Incyte Corp (INCY) 44.54 $INCY
Incyte to Report First Quarter 2014 Financial Results on May 1
Business Wire - Wed Apr 16, 7:00AM CDT
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its first quarter 2014 financial results conference call for 8:30 a.m. ET on Thursday, May 1, 2014. The schedules for the press release and conference call are as follows:
The Recent Performance of 'Baker Brother Biotech Stocks' is Awful
at The Street - Tue Apr 15, 11:23AM CDT
Healthcare's most closely followed hedge fund is losing money during the biotech bubble burst.
Global Polycythemia Vera Therapeutic Pipeline Review 2014 - Analysis of 6 Companies and 7 Drug Profiles
M2 - Tue Apr 15, 6:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fn53p5/polycythemia_vera) has announced the addition of the "Polycythemia Vera - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Polycythemia Vera, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycythemia Vera and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Polycythemia Vera - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Polycythemia Vera and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Polycythemia Vera products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Polycythemia Vera pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Polycythemia Vera - Companies Involved in Therapeutics Development - Eli Lilly and Company - Incyte Corporation - Geron Corporation - Italfarmaco S.p.A. - PharmaEssentia Corporation - miRagen Therapeutics, Inc. Drug Profiles - ruxolitinib phosphate - peginterferon alfa-2b - imetelstat sodium - givinostat - gandotinib - MGN-4893 - Small Molecules to Inhibit JAK for Oncology and Hematological Disorders For more information visit http://www.researchandmarkets.com/research/fn...hemia_vera
Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutic Pipeline Review 2014
M2 - Tue Apr 15, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/55stl2/postpolycythemia) has announced the addition of the "Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Post-Polycythemia Vera Myelofibrosis (PPV-MF) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Companies Involved in Therapeutics Development - AstraZeneca PLC - Gilead Sciences, Inc. - Novartis AG - Cell Therapeutics, Inc. - Incyte Corporation - Pharma Mar, S.A. Drug Profiles - pacritinib - momelotinib - panobinostat - plitidepsin - luminespib - simtuzumab - INCB-39110 - AZD-1480 - NS-018 - buparlisib hydrochloride For more information visit http://www.researchandmarkets.com/research/55...lycythemia
Incyte Falls 4.17% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Apr 14, 4:13PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $42.74 to a high of $48.08. Yesterday, the shares fell 4.2%, which took the trading range below the 3-day low of $46.10 on volume of 3.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Look for Shares of Incyte to Potentially Rebound after Yesterday's 4.17% Sell Off
Comtex SmarTrend(R) - Mon Apr 14, 4:10PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $42.74 to a high of $48.08. Yesterday, the shares fell 4.2%, which took the trading range below the 3-day low of $46.10 on volume of 3.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Incyte Down 22.4% Since SmarTrend Downtrend Call (INCY)
Comtex SmarTrend(R) - Mon Apr 14, 9:43AM CDT
SmarTrend identified a Downtrend for Incyte (NASDAQ:INCY) on March 21st, 2014 at $61.13. In approximately 3 weeks, Incyte has returned 22.39% as of today's recent price of $47.44.
Technical Data on Biotech Stocks -- Research on Alexion Pharma, Incyte, Merrimack Pharma, and Aastrom Biosciences
PR Newswire - Mon Apr 14, 8:00AM CDT
On Friday, April 11, 2014, the NASDAQ Composite ended at 3,999.73, down 1.34%, the Dow Jones Industrial Average declined 0.89% to 16,026.75, and the S&P 500 closed at 1,815.69, down 0.95%. The losses were broad based as all the 10 sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 644.74, down 1.07%, and the same has lost 4.46% in the last one month. Investor-Edge has initiated coverage on the following equities: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Incyte Corp. Ltd (NASDAQ: INCY), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK) and Aastrom Biosciences Inc. (NASDAQ: ASTM). Free technical research on ALXN, INCY, MACK and ASTM can be downloaded upon signing up at:
Update on Merck's MK-3475 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 5:35PM CDT
Merck presented early findings from studies assessing the efficacy of MK-3475.
After Yesterday's Decline of 2.19%, Incyte Offers Investors Better Value
Comtex SmarTrend(R) - Tue Apr 08, 5:32PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $48.13 to a high of $50.81. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $49.40 on volume of 2.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Shares of INCY Down 18.3% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Apr 07, 9:19AM CDT
SmarTrend identified a Downtrend for Incyte (NASDAQ:INCY) on March 21st, 2014 at $61.13. In approximately 2 weeks, Incyte has returned 18.31% as of today's recent price of $49.94.
Tradable Biotech Stocks Events For the Second Quarter
at The Street - Thu Apr 03, 8:00AM CDT
The biotech sector's March "fluctuation" might be a temporary speed bump or the beginning of a longer downturn. Either way, investors can still count on the biotech catalyst trade for chills and thrills.
Bear of the Day: Genomic Health (GHDX) - Bear of the Day
Kevin Cook - ZACKS - Thu Apr 03, 3:09AM CDT
Bear of the Day: Genomic Health (GHDX) - Bear of the Day
Does This Stock Warrant a $9 Billion Market Cap?
Declan Fallon, The Motley Fool - Motley Fool - Fri Mar 28, 8:30AM CDT
Incyte Pharmaceuticals has been on a tear since its only approved drug, Jakafi, won FDA approval in November 2011 for the treatment of myelofibrosis, or MF. Management projects Jakafi sales to reach up to $335 million for this year; there's also a...
The Week's Worst Clinical Failures
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 26, 1:30PM CDT
While there were plenty of winners last week, two losers stand out. The first failure belongs to GlaxoSmithKline . This giant is leading the industry with 20 new molecular entity approvals over the past six years. But its recent failure shows how...
Global Dermatological Drugs Market 2014-2018: The Global Dermatological Drugs Market is Expected to Reap Large Revenues with Increasing Use of Biologics
M2 - Wed Mar 26, 6:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/22gwrb/global) has announced the addition of the "Global Dermatological Drugs Market 2014-2018" report to their offering. The analysts forecast the Global Dermatological Drugs market to grow at a CAGR of 4.29 percent over the period 2013-2018. One of the key factors contributing to this market's growth is an increase in the aging population worldwide. The Global Dermatological Drugs market has also been witnessing a spurt in the use of biologics. However, the risk of adverse side effects associated with dermatological drugs could pose a challenge to the growth of this market. Key vendors dominating this space include AbbVie Inc., Galderma S.A., Johnson & Johnson Ltd., Novartis AG, Stiefel Laboratories Inc., and Valeant Pharmaceuticals International Inc. Other vendors mentioned in the report are Actavis plc, Allergan Inc., Almirall SA, Amgen Inc., Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Bristol Myers Squibb Co., Celgene Corp., Eisai Co. Ltd., Eli Lilly and Co., Genentech Inc., Incyte Corp., Isotechnika Inc., LEO Pharma A/S, Merck & Co. Inc., Mylan Pharmaceuticals Inc., Pfizer Inc., and UCB SA. Commenting on the report, an analyst from the team said: Biologics are manufactured proteins interfering with the immune process involved in any dermatological disorders. In recent years, the enhanced understanding of the molecular basis underlying dermatological ailment led to the introduction of biological drugs, providing a new effective treatment option for dermatological disorders. Biologics emphasizes on specific aspects of the immune function that result in any illness. Along with topical treatments, the current market is crowded with biologics for dermatology. Amgen/Wyeth's Enbrel continues to hold its position as market leader amongst biologics; however, Abbott's Humira has increased its share significantly in the past year. For more information visit http://www.researchandmarkets.com/research/22gwrb/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Pre-market Biotech Picks -- Research on Merrimack Pharma, Alexion Pharma, Incyte, and Aastrom Biosciences
PR Newswire - Tue Mar 25, 10:25AM CDT
On Monday, March 24, 2014, the NASDAQ Composite ended at 4,226.39, down 1.18%, the Dow Jones Industrial Average declined 0.16% to 16,276.69, and the S&P 500 closed at 1,857.44, down 0.49%. The losses were broad based as 8 out of 10 sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 666.18, down 1.41%, and the same has fallen by 2.67% in the last one month. Investor-Edge has initiated coverage on the following equities: Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Incyte Corp. Ltd (NASDAQ: INCY) and Aastrom Biosciences Inc. (NASDAQ: ASTM). Free technical research on MACK, ALXN, INCY and ASTM can be downloaded upon signing up at:
Is Incyte Corporation Overvalued?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue Mar 25, 8:30AM CDT
One of the secrets to successful stockpicking in the biotech sector is adequately valuing and pricing the risk/reward profile of a company's pipeline. Almost every biotech looks cheap if an investor just assumes that everything will work as planned,...
Incyte to Report First Quarter 2014 Financial Results on May 1
Business Wire - Wed Apr 16, 7:00AM CDT
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its first quarter 2014 financial results conference call for 8:30 a.m. ET on Thursday, May 1, 2014. The schedules for the press release and conference call are as follows:
The Recent Performance of 'Baker Brother Biotech Stocks' is Awful
at The Street - Tue Apr 15, 11:23AM CDT
Healthcare's most closely followed hedge fund is losing money during the biotech bubble burst.
Global Polycythemia Vera Therapeutic Pipeline Review 2014 - Analysis of 6 Companies and 7 Drug Profiles
M2 - Tue Apr 15, 6:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fn53p5/polycythemia_vera) has announced the addition of the "Polycythemia Vera - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Polycythemia Vera, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycythemia Vera and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Polycythemia Vera - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Polycythemia Vera and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Polycythemia Vera products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Polycythemia Vera pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Polycythemia Vera - Companies Involved in Therapeutics Development - Eli Lilly and Company - Incyte Corporation - Geron Corporation - Italfarmaco S.p.A. - PharmaEssentia Corporation - miRagen Therapeutics, Inc. Drug Profiles - ruxolitinib phosphate - peginterferon alfa-2b - imetelstat sodium - givinostat - gandotinib - MGN-4893 - Small Molecules to Inhibit JAK for Oncology and Hematological Disorders For more information visit http://www.researchandmarkets.com/research/fn...hemia_vera
Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutic Pipeline Review 2014
M2 - Tue Apr 15, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/55stl2/postpolycythemia) has announced the addition of the "Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Post-Polycythemia Vera Myelofibrosis (PPV-MF) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Companies Involved in Therapeutics Development - AstraZeneca PLC - Gilead Sciences, Inc. - Novartis AG - Cell Therapeutics, Inc. - Incyte Corporation - Pharma Mar, S.A. Drug Profiles - pacritinib - momelotinib - panobinostat - plitidepsin - luminespib - simtuzumab - INCB-39110 - AZD-1480 - NS-018 - buparlisib hydrochloride For more information visit http://www.researchandmarkets.com/research/55...lycythemia
Incyte Falls 4.17% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Apr 14, 4:13PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $42.74 to a high of $48.08. Yesterday, the shares fell 4.2%, which took the trading range below the 3-day low of $46.10 on volume of 3.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Look for Shares of Incyte to Potentially Rebound after Yesterday's 4.17% Sell Off
Comtex SmarTrend(R) - Mon Apr 14, 4:10PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $42.74 to a high of $48.08. Yesterday, the shares fell 4.2%, which took the trading range below the 3-day low of $46.10 on volume of 3.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Incyte Down 22.4% Since SmarTrend Downtrend Call (INCY)
Comtex SmarTrend(R) - Mon Apr 14, 9:43AM CDT
SmarTrend identified a Downtrend for Incyte (NASDAQ:INCY) on March 21st, 2014 at $61.13. In approximately 3 weeks, Incyte has returned 22.39% as of today's recent price of $47.44.
Technical Data on Biotech Stocks -- Research on Alexion Pharma, Incyte, Merrimack Pharma, and Aastrom Biosciences
PR Newswire - Mon Apr 14, 8:00AM CDT
On Friday, April 11, 2014, the NASDAQ Composite ended at 3,999.73, down 1.34%, the Dow Jones Industrial Average declined 0.89% to 16,026.75, and the S&P 500 closed at 1,815.69, down 0.95%. The losses were broad based as all the 10 sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 644.74, down 1.07%, and the same has lost 4.46% in the last one month. Investor-Edge has initiated coverage on the following equities: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Incyte Corp. Ltd (NASDAQ: INCY), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK) and Aastrom Biosciences Inc. (NASDAQ: ASTM). Free technical research on ALXN, INCY, MACK and ASTM can be downloaded upon signing up at:
Update on Merck's MK-3475 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 5:35PM CDT
Merck presented early findings from studies assessing the efficacy of MK-3475.
After Yesterday's Decline of 2.19%, Incyte Offers Investors Better Value
Comtex SmarTrend(R) - Tue Apr 08, 5:32PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $48.13 to a high of $50.81. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $49.40 on volume of 2.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Shares of INCY Down 18.3% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Apr 07, 9:19AM CDT
SmarTrend identified a Downtrend for Incyte (NASDAQ:INCY) on March 21st, 2014 at $61.13. In approximately 2 weeks, Incyte has returned 18.31% as of today's recent price of $49.94.
Tradable Biotech Stocks Events For the Second Quarter
at The Street - Thu Apr 03, 8:00AM CDT
The biotech sector's March "fluctuation" might be a temporary speed bump or the beginning of a longer downturn. Either way, investors can still count on the biotech catalyst trade for chills and thrills.
Bear of the Day: Genomic Health (GHDX) - Bear of the Day
Kevin Cook - ZACKS - Thu Apr 03, 3:09AM CDT
Bear of the Day: Genomic Health (GHDX) - Bear of the Day
Does This Stock Warrant a $9 Billion Market Cap?
Declan Fallon, The Motley Fool - Motley Fool - Fri Mar 28, 8:30AM CDT
Incyte Pharmaceuticals has been on a tear since its only approved drug, Jakafi, won FDA approval in November 2011 for the treatment of myelofibrosis, or MF. Management projects Jakafi sales to reach up to $335 million for this year; there's also a...
The Week's Worst Clinical Failures
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 26, 1:30PM CDT
While there were plenty of winners last week, two losers stand out. The first failure belongs to GlaxoSmithKline . This giant is leading the industry with 20 new molecular entity approvals over the past six years. But its recent failure shows how...
Global Dermatological Drugs Market 2014-2018: The Global Dermatological Drugs Market is Expected to Reap Large Revenues with Increasing Use of Biologics
M2 - Wed Mar 26, 6:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/22gwrb/global) has announced the addition of the "Global Dermatological Drugs Market 2014-2018" report to their offering. The analysts forecast the Global Dermatological Drugs market to grow at a CAGR of 4.29 percent over the period 2013-2018. One of the key factors contributing to this market's growth is an increase in the aging population worldwide. The Global Dermatological Drugs market has also been witnessing a spurt in the use of biologics. However, the risk of adverse side effects associated with dermatological drugs could pose a challenge to the growth of this market. Key vendors dominating this space include AbbVie Inc., Galderma S.A., Johnson & Johnson Ltd., Novartis AG, Stiefel Laboratories Inc., and Valeant Pharmaceuticals International Inc. Other vendors mentioned in the report are Actavis plc, Allergan Inc., Almirall SA, Amgen Inc., Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Bristol Myers Squibb Co., Celgene Corp., Eisai Co. Ltd., Eli Lilly and Co., Genentech Inc., Incyte Corp., Isotechnika Inc., LEO Pharma A/S, Merck & Co. Inc., Mylan Pharmaceuticals Inc., Pfizer Inc., and UCB SA. Commenting on the report, an analyst from the team said: Biologics are manufactured proteins interfering with the immune process involved in any dermatological disorders. In recent years, the enhanced understanding of the molecular basis underlying dermatological ailment led to the introduction of biological drugs, providing a new effective treatment option for dermatological disorders. Biologics emphasizes on specific aspects of the immune function that result in any illness. Along with topical treatments, the current market is crowded with biologics for dermatology. Amgen/Wyeth's Enbrel continues to hold its position as market leader amongst biologics; however, Abbott's Humira has increased its share significantly in the past year. For more information visit http://www.researchandmarkets.com/research/22gwrb/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Pre-market Biotech Picks -- Research on Merrimack Pharma, Alexion Pharma, Incyte, and Aastrom Biosciences
PR Newswire - Tue Mar 25, 10:25AM CDT
On Monday, March 24, 2014, the NASDAQ Composite ended at 4,226.39, down 1.18%, the Dow Jones Industrial Average declined 0.16% to 16,276.69, and the S&P 500 closed at 1,857.44, down 0.49%. The losses were broad based as 8 out of 10 sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 666.18, down 1.41%, and the same has fallen by 2.67% in the last one month. Investor-Edge has initiated coverage on the following equities: Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Incyte Corp. Ltd (NASDAQ: INCY) and Aastrom Biosciences Inc. (NASDAQ: ASTM). Free technical research on MACK, ALXN, INCY and ASTM can be downloaded upon signing up at:
Is Incyte Corporation Overvalued?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue Mar 25, 8:30AM CDT
One of the secrets to successful stockpicking in the biotech sector is adequately valuing and pricing the risk/reward profile of a company's pipeline. Almost every biotech looks cheap if an investor just assumes that everything will work as planned,...
